Kidney Cancer Clinical Trial

Clinical Trial Finder Kidney Cancer Trials

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

See Locations Near You

Summary

The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component
Previous treatment with at least one anti-angiogenic agent
Progressed within 6 months of study enrollment
Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease
Must have available tumor tissue for submission
Subjects must also meet various laboratory parameters for inclusion

Exclusion Criteria:

Subjects with any active autoimmune disease or a history of known autoimmune disease

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

168

Study ID:

NCT01354431

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 39 Locations for this study

See Locations Near You

UCSD Moores Cancer Center
La Jolla California, 92093, United States
Ucla
Los Angeles California, 90024, United States
Samuel Oschin Comprehensive Cancer Inst.
Los Angeles California, 90048, United States
Stanford Cancer Center
Stanford California, 94305, United States
University Of Colorado
Aurora Colorado, 80045, United States
Georgetown University Medical Center
Washington District of Columbia, 20007, United States
Northwestern University Feinberg School Of Medicine
Chicago Illinois, 60611, United States
Loyola University Medical Center
Maywood Illinois, 60153, United States
Indiana University Health Melvin And Bren Simon Cancer Center
Indianapolis Indiana, 46202, United States
University Of Kansas Medical Center
Kansas City Kansas, 66160, United States
University Of Maryland
Baltimore Maryland, 21201, United States
The Bunting-Blaustein Cancer Research Building
Baltimore Maryland, 21287, United States
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States
Beth Israel Deaconess Medical Ctr.
Boston Massachusetts, 02215, United States
University Of Michigan Medical Center
Ann Arbor Michigan, 48109, United States
Wayne State University
Detroit Michigan, 48201, United States
Masonic Cancer Ctr, University Of Minnesota
Minneapolis Minnesota, 55455, United States
North Mississippi Hematology And Oncology Associates, Ltd
Tupelo Mississippi, 38801, United States
Dartmouth-Hitchcock Medical Center
Lebanon New Hampshire, 03756, United States
Roswell Park Cancer Institute
Buffalo New York, 14263, United States
St. Luke'S Roosevelt Hospital Center
New York New York, 10019, United States
Mount Sinai Medical Center
New York New York, 10029, United States
Memorial Sloan Kettering Nassau
New York New York, 10065, United States
Weill Cornell Medical College
New York New York, 10065, United States
Blumenthal Cancer Center
Charlotte North Carolina, 28204, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
University Of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
Medical University Of South Carolina
Charleston South Carolina, 29425, United States
Tennessee Oncology, PLLC
Nashville Tennessee, 37203, United States
Vanderbilt-Ingram Cancer Ctr
Nashville Tennessee, 37232, United States
University of Washington - Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
Wheaton Franciscan Health Care
Wauwatosa Wisconsin, 53226, United States
Tom Baker Cancer Centre
Calgary Alberta, T2N 4, Canada
Centre D'Oncologie Dr-Leon-Richard
Moncton New Brunswick, E1C 8, Canada
Local Institution
Halifax Nova Scotia, B3H 2, Canada
London Regional Cancer Program
London Ontario, N6A 4, Canada
Centre Hospitalier Universitaire De Montreal-Notre-Dame Hosp
Montreal Quebec, H2L 4, Canada
Local Institution
Helsinki , 00029, Finland
Local Institution
Siena , 53100, Italy
Load More

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Phase:

Phase 2

Estimated Enrollment:

168

Study ID:

NCT01354431

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider